Ceribell vs Pulmonx
Pulmonx reported revenue of $90 million in fiscal 2025, about the same as Ceribell's $89 million in fiscal 2025. Ceribell's revenue grew 36.1% in its latest year, and Pulmonx's grew 8.0%. Ceribell had an operating margin of -65.6%, against -59.3% at Pulmonx. Free cash flow was −$42 million at Ceribell and −$33 million at Pulmonx.
Side by side
| Ceribell | Pulmonx | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $89M | $90M |
| Revenue growth | 36.1% | 8.0% |
| Revenue growth a year, last 5 years | — | 22.6% |
| Gross margin | 87.9% | 74.2% |
| Operating margin | −65.6% | −59.3% |
| Net margin | −60.0% | −59.7% |
| Free cash flow | −$42M | −$33M |
| Free cash flow margin | −46.7% | −36.3% |
| Return on capital | — | −183.3% |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 205.8% | 4.0% |
| Last close | $25.75 | $2.74 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $23.3 million | sold $547,894 |
| Piotroski F-score | — | 3 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
CeribellPulmonx
Operating margin
Percent of revenue
CeribellPulmonx
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
CeribellPulmonx